Deutsche Bank’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Deutsche Bank’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20	Closed	-$13K	–	4375
2019 Q4	$13K	Buy	+20	New	+$10.7K	﹤0.01%	4418
2015 Q2	–	Sell	-2	Closed	-$16K	–	5339
2015 Q1	$16K	Sell	2 -37	-95%	-$445K	﹤0.01%	4714
2014 Q4	$409K	Hold	39	–	–	﹤0.01%	3811
2014 Q3	$382K	Hold	39	–	–	﹤0.01%	3671
2014 Q2	$417K	Hold	39	–	–	﹤0.01%	3603
2014 Q1	$587K	Buy	+39	New	+$667K	﹤0.01%	3228

Other funds holding CANF

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Deutsche Bank's CANF Position: Q1 2020 in Review

Deutsche Bank sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2020, closing a stake of 20 shares — an estimated $13K sold.

Deutsche Bank first reported a position in CANF in Q1 2014 and held it in 6 quarters. The position peaked at $587K in Q1 2014. 4 funds tracked by Wall St. Rank hold CANF as of Q1 2020.

Deutsche Bank reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q1 2020 after selling out during the quarter.
Deutsche Bank sold 20 Can-Fite BioPharma American Depositary Shares shares in Q1 2020, an estimated $13K.
Deutsche Bank first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2014 and held it in 6 quarters.
Deutsche Bank's Can-Fite BioPharma American Depositary Shares position peaked at $587K in Q1 2014.
4 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.